# Rho Federal Systems Division, Inc. NIAID DAIT SACCC

> **NIH NIH UM2** · RHO FEDERAL SYSTEMS DIVISION, INC. · 2021 · $3,499,987

## Abstract

PROJECT SUMMARY/ABSTRACT—OVERALL COMPONENT
 Through this Funding Opportunity Announcement, the NIAID Division of Allergy, Immunology and
Transplantation (DAIT) intends to consolidate its funding for multiple, independent Statistical and Clinical
Coordinating Centers (SACCCs) into a single multi-component cooperative agreement, presumably to reduce
costs and increase efficiency and standardization across research consortia. This new program will fund a
single SACCC, or Center, to support DAIT research in the areas of asthma and allergic diseases, autoimmune
diseases, and transplantation. Because Rho is currently the SACCC for many of these consortia and these
SACCCs already share some resources and processes, Rho is well suited to provide consolidated support.
 The objective of the Center is to provide excellent and efficient coordination of the following services:
protocol development, study initiation and management, statistical design and analysis, clinical site monitoring,
ancillary services, data management, safety oversight, and bioinformatics. To accomplish these objectives,
Rho aims to (1) provide staff experienced in research conducted by DAIT-supported consortia and to organize
these staff in an administrative structure that manages resources efficiently, is responsive to the needs of the
research consortia and DAIT, and facilitates communication and collaboration; (2) provide experienced
scientists and statisticians who, in collaboration with clinical investigators and DAIT officials, design and
analyze studies across the full scope of research; (3) facilitate the development, review, and revision of initial
and successive drafts of protocols and protocol-related documents through dedicated protocol teams; (4)
provide study initiation and study management functions that are required for the efficient, valid, and ethical
conduct of studies; (5) provide high-quality and well-developed procedures and personnel for the monitoring of
clinical sites; (6) provide the efficient and accurate tracking and reconciliation of specimen collection and
distribution; (7) provide high-quality, integrated, and secure information management systems and procedures
for the collection of clinical and mechanistic data; (8) help ensure patient safety by providing high-quality
serious adverse event (SAE) reporting and Data and Safety Monitoring Board (DSMB) reports; and (9) provide
tools, infrastructure, and analytical support in the planning, implementation, analysis, and dissemination of high
dimensional mechanistic studies.
 Based on our substantial experience coordinating all aspects of clinical research, we plan to use our
current technology infrastructure, combined with new and innovative techniques to: streamline and automate
processes; provide easy access to data for DAIT, clinical investigators, and other key research stakeholders;
allow for flexibility of Center staffing and resource sharing; standardize processes and methodologies across
disease group...

## Key facts

- **NIH application ID:** 10457674
- **Project number:** 3UM2AI117870-07S3
- **Recipient organization:** RHO FEDERAL SYSTEMS DIVISION, INC.
- **Principal Investigator:** Samuel Arbes
- **Activity code:** UM2 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2021
- **Award amount:** $3,499,987
- **Award type:** 3
- **Project period:** 2021-08-31 → 2023-04-30

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10457674

## Citation

> US National Institutes of Health, RePORTER application 10457674, Rho Federal Systems Division, Inc. NIAID DAIT SACCC (3UM2AI117870-07S3). Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/grant/nih/10457674. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*